Manhattan Scientifics : MHTX Former Wholly Owned Sub Announces Breast Cancer Diagnostic Test Begin with First-in-Human Study
December 17, 2020 at 09:21 am EST
Share
December 17, 2020
Click here to view the printer friendly version of this press release
Manhattan Scientifics Inc. (MHTX: OTCQB) announces that the first 15-person human study to provide a safety assessment for the company's use of Nanoparticles for breast cancer detection is underway at Imagion Biosystems Inc. Trades as IBX.AX.
The study is the first clinical investigation of Imagion Biosystems' MagSense™ nanoparticles that target HER2 positive tumor cells as a means of helping in breast cancer diagnosis by identifying if patient's tumor has spread to the lymph nodes.
Manhattan Scientifics Inc, an American medical technology incubator that seed funded IBX and then spun it out as a public company on the Australian stock exchange. Manhattan Scientifics owns more than 50 million IBX shares and remains as the largest single shareholder of IBX.
To learn more about the study visit the link below:
Imagion Biosystems first in-human study update - webcast presentation
About Manhattan Scientifics
Manhattan Scientifics Inc. (www.mhtx.com) is focused on commercialization of disruptive technologies in the nano medicine space.
Forward-looking statement
This press release contains forward-looking statements, which are subject to a number of risks, assumptions and uncertainties that could cause the Company's actual results to differ materially from those projected in such forward-looking statements. Management at Manhattan Scientifics believes that purchase of its shares should be considered to be at the high end of the risk spectrum. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements.
Attachments
Original document
Permalink
Disclaimer
Manhattan Scientifics Inc. published this content on 17 December 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 17 December 2020 14:20:03 UTC
Manhattan Scientifics, Inc. is focused on technology transfer and commercialization of these transformative technologies. The Company operates as a technology incubator. Its business model is to identify significant technologies; acquire them or the rights to them; secure the services of inventors, engineers or other staff who were instrumental in their creation; provide or contract for suitable work facilities, laboratories, and other aids where appropriate; prototype the technologies to demonstrate proof of principle feasibility; secure patent and or other intellectual property protection; secure early customers for product trials where feasible and appropriate; and commercialize through licenses, sales or cooperative efforts with other manufacturing and distribution firms. Its business model is based on licensing metals technology to metals manufacturers. Its technologies are in a development phase.